DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It
Two listed healthcare companies agreed to go private before lunch on Monday. Eighty seven cents of every announced dollar was paid at signing.
Big Billion Deals
Curium’s CVR Waterfall Says It Trusts DEFINITY, Is Betting on Neurology, and Doubts Prostate
Curium locked 89.5% of consideration in cash and hung the rest on prostate. The CVR waterfall is the buyer’s own forecast, published.
DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line
Thirty four healthcare deals crossed the wire the week of July 13, 2026. Four of the five that matter paid cash for something that already works: an operating rare-disease pharmacy, an FDA-approved drug, a Phase 3 asset with Breakthrough.
Boulevard Bio Secures Global Rights to a $1.6B Trispecific T-Cell Engager
Boulevard Bio is paying $20 million upfront and committing up to $1.6 billion in milestones for the global rights to MTS-128, a trispecific T-cell engager.
Cidara Therapeutics Stock sky-Rockets on $9B Merck buyout
Merck’s $9.2 billion acquisition of Cidara brings CD388, a Phase 3 long-acting influenza antiviral, into its pipeline while adding the Cloudbreak® drug-Fc conjugate platform for future oncology and infectious-disease programs.
Takeover Battle: Novo Nordisk Wins Brave Court Victory in $10B Metsera Deal Amid FTC Probe
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
Novo’s unsolicited bid for Metsera challenges Pfizer pact
Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
The Big Bet: Health Care Deal Spotlight for September 1 to 7, 2025)
Healthcare deal spotlight September 1 to 7, 2025